Compare FBYD & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBYD | EBS |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.3M | 312.8M |
| IPO Year | 2023 | 2006 |
| Metric | FBYD | EBS |
|---|---|---|
| Price | $7.41 | $6.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 119.9K | ★ 1.1M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ 0.04 | N/A |
| Revenue | $14,896,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $168.75 | ★ N/A |
| Revenue Growth | ★ 120.85 | N/A |
| 52 Week Low | $3.71 | $4.36 |
| 52 Week High | $29.02 | $14.06 |
| Indicator | FBYD | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 58.64 |
| Support Level | $5.80 | $5.50 |
| Resistance Level | $8.08 | $7.05 |
| Average True Range (ATR) | 0.75 | 0.33 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 52.85 | 83.55 |
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.